Description
+ Include: 23 videos + 24 pdfs, size: 2.49 GB
+ Target Audience: oncologist
+ Sample video: contact me for sample video
+ Information:
- Start date 19 May 2023
- End date 20 May 2023
- Location Valencia, Spain
Learning objectives
- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology, histo- and moleculopathological prognostic factors
- To learn about sequencing of treatments, adverse events and special situations
+ Topics:
ESMO-Preceptorship-on-Colorectal-Cancer-2023-Valencia-Programme.pdf
Session 1 Adjuvant Treatment for Colon Cancer Stage II and III as Standard of Care.mp4
Session 1 Adjuvant Treatment for Colon Cancer Stage II and III as Standard of Care.pdf
Session 1 Neoadjuvant Chemotherapy for Localised Colon Cancer as a Potential Option.mp4
Session 1 Neoadjuvant Chemotherapy for Localised Colon Cancer as a Potential Option.pdf
Session 1 Quality and Rules of a Good Pathology Report – Histo- and Moleculopathological Biomarkers.mp4
Session 1 Quality and Rules of a Good Pathology Report – Histo- and Moleculopathological Biomarkers.pdf
Session 2 Neoadjuvant Immunotherapy for Localised Colorectal Cancer Facts and Future Prospective.mp4
Session 2 Neoadjuvant Immunotherapy for Localised Colorectal Cancer Facts and Future Prospective.pdf
Session 2 Participants Clinical Case Discussion on Localised Colon Cancer – ctDNA Monitoring in Localized Colon Cancer Evidences.mp4
Session 2 Participants Clinical Case Discussion on Localised Colon Cancer – ctDNA Monitoring in Localized Colon Cancer Evidences.pdf
Session 2 Participants Clinical Case Discussion on Localised Colon Cancer – Managing Locally Advanced dMMR Colon Cancer with Neoadjuvant Immunotherapy.mp4
Session 2 Participants Clinical Case Discussion on Localised Colon Cancer – Managing Locally Advanced dMMR Colon Cancer with Neoadjuvant Immunotherapy.pdf
Session 2 Participants Clinical Case Discussion on Localised Colon Cancer – Total Neoadjuvant Therapy for Rectal Cancer.mp4
Session 2 Participants Clinical Case Discussion on Localised Colon Cancer – Total Neoadjuvant Therapy for Rectal Cancer.pdf
Session 3 Current Treatment of Metastatic Colorectal Cancer Basic Strategies According to Clinical and Molecular Subgroups MSI-H.mp4
Session 3 Current Treatment of Metastatic Colorectal Cancer Basic Strategies According to Clinical and Molecular Subgroups MSI-H.pdf
Session 3 Presentation of Three Challenging Clinical Cases by the Expert and Faculty Discussion.mp4
Session 3 Presentation of Three Challenging Clinical Cases by the Expert and Faculty Discussion.pdf
Session 4 How to Integrate Surgery in the Treatment of Patients with Liver-only Metastatic Disease.mp4
Session 4 How to Integrate Surgery in the Treatment of Patients with Liver-only Metastatic Disease.pdf
Session 4 Oligometastatic Colorectal Cancer What to Know about it and How to Treat it.mp4
Session 4 Oligometastatic Colorectal Cancer What to Know about it and How to Treat it.pdf
Session 4 Participants Clinical Case Discussion – A DPYD Variant with mCRC and Inoperable Liver Metastasis.mp4
Session 4 Participants Clinical Case Discussion – A DPYD Variant with mCRC and Inoperable Liver Metastasis.pdf
Session 4 Participants Clinical Case Discussion – Maintenance Treatment with Cetuximab in RAS Wild-type Metastatic Colorectal Cancer.mp4
Session 4 Participants Clinical Case Discussion – Maintenance Treatment with Cetuximab in RAS Wild-type Metastatic Colorectal Cancer.pdf
Session 4 Participants Clinical Case Discussion – Surgery and Triplet Chemotherapy with Liver-only Metastatic Disease.mp4
Session 4 Participants Clinical Case Discussion – Surgery and Triplet Chemotherapy with Liver-only Metastatic Disease.pdf
Session 5 How to Deal with Patients with BRAF Mutant and HER2 Amplified Advanced Colorectal Cancer after 1st Failure.mp4
Session 5 How to Deal with Patients with BRAF Mutant and HER2 Amplified Advanced Colorectal Cancer after 1st Failure.pdf
Session 5 Management of Treatment-related Side Effects.mp4
Session 5 Management of Treatment-related Side Effects.pdf
Session 5 Treating Patients with Chemorefractory Disease Challenges and Opportunities.mp4
Session 5 Treating Patients with Chemorefractory Disease Challenges and Opportunities.pdf
Session 5 What to Do after First-line Failure.mp4
Session 5 What to Do after First-line Failure.pdf
Session 6 Standard of Care of Localised Rectal Cancer.mp4
Session 6 Standard of Care of Localised Rectal Cancer.pdf
Session 7 Participants Clinical Case Discussion – Encorafenib Plus Cetuximab after First-line Immunotherapy in dMMR BRAF V600E Metastatic Colorectal Cancer.mp4
Session 7 Participants Clinical Case Discussion – Encorafenib Plus Cetuximab after First-line Immunotherapy in dMMR BRAF V600E Metastatic Colorectal Cancer.pdf
Session 7 Participants Clinical Case Discussion – Great Response in 2L with a KRAS G12C Inhibitor More Proof that KRAS is Indeed Druggable.mp4
Session 7 Participants Clinical Case Discussion – Great Response in 2L with a KRAS G12C Inhibitor More Proof that KRAS is Indeed Druggable.pdf
Session 7 Participants Clinical Case Discussion – HER-2 in Colorectal Cancer Success Story.mp4
Session 7 Participants Clinical Case Discussion – HER-2 in Colorectal Cancer Success Story.pdf
Welcome and Introduction.mp4
Welcome and Introduction.pdf
Reviews
There are no reviews yet.